Mora Samia, Rifai Nader, Buring Julie E, Ridker Paul M
Donald W. Reynolds Center for Cardiovascular Research, Brigham and Women's Hospital, 900 Commonwealth Ave E, Boston, MA 02215.
Circulation. 2006 Aug 1;114(5):381-7. doi: 10.1161/CIRCULATIONAHA.106.634089. Epub 2006 Jul 24.
Current guidelines suggest measuring high-sensitivity C-reactive protein (hs-CRP) as an aid to coronary risk assessment in adults without cardiovascular disease (CVD). Whether other inflammatory biomarkers, such as fibrinogen, add further prognostic information is uncertain.
In a prospective study of 27,742 initially healthy middle-aged women, the associations of baseline immunoassay fibrinogen and hs-CRP measurements with incident CVD were examined over a 10-year follow-up period. Compared with women in the bottom biomarker quintile, age-adjusted hazard ratios (95% confidence intervals [CIs]) for incident CVD for quintiles 2 to 5 of fibrinogen were 1.10 (0.86 to 1.41), 1.30 (1.03 to 1.65), 1.46 (1.16 to 1.85), and 2.43 (1.95 to 3.02); for hs-CRP they were 1.48 (1.06 to 2.05), 1.70 (1.24 to 2.33), 2.20 (1.63 to 2.96), and 3.24 (2.43 to 4.31). After further adjustment for established risk factors, both biomarkers remained associated (P for trend < or = 0.001) with incident CVD (hazard ratio, 1.35; 95% CI, 1.07 to 1.71 for top fibrinogen quintile; and hazard ratio, 1.68; 95% CI, 1.22 to 2.29 for top hs-CRP quintile compared with the bottom quintiles). Further adjustment for the other biomarker resulted in hazard ratios of 1.23 and 1.56 (P for trend = 0.02 and 0.002), respectively. Although fibrinogen correlated positively with hs-CRP (rs = 0.41, P < 0.001), the highest CVD risk was associated with elevated levels of both fibrinogen and hs-CRP: age-adjusted hazard ratio of 3.45 (95% CI, 2.60 to 4.57) for women with fibrinogen > 393 mg/dL and hs-CRP > 3 mg/L compared with < 329 mg/dL and < 1 mg/L, respectively.
In this cohort of initially healthy women, baseline levels of fibrinogen measured with a high-quality immunoassay provided additive value to hs-CRP and traditional risk factors in predicting incident CVD.
当前指南建议检测高敏C反应蛋白(hs-CRP),以辅助对无心血管疾病(CVD)的成年人进行冠心病风险评估。其他炎症生物标志物,如纤维蛋白原,是否能提供更多预后信息尚不确定。
在一项对27742名起初健康的中年女性进行的前瞻性研究中,在10年随访期内检测了基线免疫分析法纤维蛋白原和hs-CRP测量值与CVD发病之间的关联。与生物标志物处于最低五分位数的女性相比,纤维蛋白原五分位数2至5组发生CVD的年龄调整风险比(95%置信区间[CI])分别为1.10(0.86至1.41)、1.30(1.03至1.65)、1.46(1.16至1.85)和2.43(1.95至3.02);hs-CRP的分别为1.48(1.06至2.05)、1.70(1.24至2.33)、2.20(1.63至2.96)和3.24(2.43至4.31)。在进一步调整既定风险因素后,两种生物标志物仍与CVD发病相关(趋势P值≤0.001)(最高纤维蛋白原五分位数组的风险比为1.35;95%CI为1.07至1.71;最高hs-CRP五分位数组与最低五分位数组相比,风险比为1.68;95%CI为1.22至2.29)。对另一种生物标志物进行进一步调整后,风险比分别为1.23和1.56(趋势P值分别为0.02和0.002)。尽管纤维蛋白原与hs-CRP呈正相关(rs = 0.41,P < 0.001),但CVD风险最高与纤维蛋白原和hs-CRP水平均升高相关:纤维蛋白原>393 mg/dL且hs-CRP>3 mg/L的女性与纤维蛋白原<329 mg/dL且hs-CRP<1 mg/L的女性相比,年龄调整风险比为3.45(95%CI为2.60至4.57)。
在这一起初健康的女性队列中,采用高质量免疫分析法测量的基线纤维蛋白原水平在预测CVD发病方面为hs-CRP和传统风险因素提供了附加价值。